PDF下载 ( 155 KB)
Interactions of nonalcoholic fatty liver disease with metabolic syndrome and chronic viral hepatitis: an emphasis on Taiwan experience sharing
-
-
2023年8月25日，中华医学会关于“2023年度中华医学科技论文TOP100”遴选结果的公示结束。继2022年首次参评并入选1篇文章之后，《临床肝胆病杂志》2023年度2篇推选文章——2020年36卷第2期《慢性乙型肝炎患者肝脏硬度值下降趋势与肝纤维化逆转结局的关系》、2021年37卷第7期《基于瞬时弹性成像技术检测参数的非酒精性脂肪性肝病进展评估模型的建立》，再度荣膺“中华医学科技论文TOP100”。
中国科协优秀科技论文遴选工作由中国科学技术协会组织，自2016年始，每年举办一届，2023年为第八届。为鼓励科技工作者切实加强基础研究和关键核心技术攻关，将更多高水平研究成果在国内期刊发表，从源头推动我国科技期刊高质量发展而举办。遴选工作分10个学科集群进行，每个学科集群由1家全国学会牵头负责集群内论文遴选工作。中华医学会每年承担中国科协优秀科技论文遴选（临床医学集群）牵头工作，同时面向全国医药卫生领域期刊开展当年度“中华医学科技论文TOP100”评选活动。2023年度TOP100入选论文将通过专家现场评审，从中遴选22篇（包括10篇临床研究型、10篇基础研究型、2篇综述型）作为入选第八届中国科协优秀科技论文（临床医学集群）的候选论文推荐至中国科协。更多详情请见： http://top100.medline.org.cn/。
《临床肝胆病杂志》编辑部 2023年11月20日 -
[1]Sanyal AJ.American Gastroenterological Association.AGA technical review on nonalcoholic fatty liver disease[J].Gastroenterology, 2002, 123 (5) :1705-1725. [2]American Gastroenterological Association Medical Position Statement:Nonalcoholic fatty liver disease[J].Gastroenterology, 2002, 123 (5) :1702-1704. [3]Angulo P.Nonalcoholic fatty liver disease[J].N Engl J Med, 2002, 346 (16) :1221-1231. [4]Bugianesi E, Leone N, Vanni E, et al.Expanding the natural histo-ry of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepa-tocellular carcinoma[J].Gastroenterology, 2002, 123 (1) :134-140. [5]Caldwell SH, Oelsner DH, Iezzoni JC, et al.Cryptogenic cirrhosis:clinical characterization and risk factors for underlying disease[J].Hepatology, 1999, 29 (3) :664-669. [6]Kumar KS, Malet PF.Nonalcoholic steatohepatitis[J].Mayo Clin Proc, 2000, 75 (7) :733-739. [7]Neuschwander-Tetri BA.Nonalcoholic steatohepatitis:Summary of an AASLD single topic conference[J].Hepatology, 2003, 37 (5) :1202-1219. [8]Reid AE.Nonalcoholic steatohepatiits[J].Gastroenterology, 2001, 121 (3) :710-723. [9]Farrell GC.Nonalcoholic fatty liver disease:from steatosis to cirrho-sis[J].Hepatology, 2006, 43 (2suppl1) :S99-S112. [10]Falck-Ytter Y, Younossi ZM, Marchesini G, et al.Clinical fea-tures and natural history of nonalcoholic steatosis syndromes[J].Se-min Liver Dis, 2001, 21 (1) :17-26. [11]Ruhl CE, Everhart JE.Determinants of the association of over-weight with elevated serum alanine aminotransferase activity in the U-nited States[J].Gastroenterology, 2003, 124 (1) :71-79. [12]Youssef W, McCullough AJ.Diabetes mellitus, obesity, and hepat-ic steatosis[J].Semin Gastrointest Dis, 2002, 13 (1) :17-30. [13]Chang HY, Yeh WT, Chang YH, et al.Prevalence of dyslipidemia and mean blood lipid values in Taiwan:results fromthe Nutrition andHealth Survey in Taiwan (NAHSIT, 1993-1996) [J].Chin J Physiol, 2002, 45 (4) :187-197. [14]Lin YC, Yen LL, Chen SY, et al.Prevalence of overweight and o-besity and its associated factors:findings from National Nutrition and Health Survey in Taiwan, 1993-1996[J].Prev Med, 2003, 37 (3) :233-241. [15]Pan WH, Chang HY, Yeh WT, et al.Prevalence, awareness, treat-ment and control of hypertension in Taiwan:results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996[J].J Hum Hy-pertens, 2001, 15 (11) :793-798. [16]WEI JN, SUNG FC, LIN CC et al.National surveillance for type II diabetes mellitus in Taiwanese children[J].JAMA, 2003, 290 (10) :1345-1350. [17]Hwang LC, Bai CH, Chen CJ.Prevalence of obesity and metabolic syndrome in Taiwan[J].J Formos Med Assoc, 2006, 105 (8) :626-635. [18]Brunt EM.Nonalcoholic steatohepatitis:Definition and pathology[J].Semin Liver Dis, 2001, 21 (1) :3-16. [19]Ludwig J, Viggiano TR, McGill DB, et al.Nonalcoholic steatohepa-titis:Mayo Clinic experiences with a hitherto unnamed disease[J].Mayo Clin Proc, 1980, 55 (7) :434-438. [20]Wanless IR, Lentz JS.Fatty liver hepatitis (steatohepatitis) and o-besity:an autopsy study with analysis of risk factors[J].Hepatolo-gy, 1990, 12 (5) :1106-1110. [21]Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al.Idio-pathic steatohepatitis in childhood:a multicenter retrospective study[J].J Pediatr, 1995, 127 (5) :700-704. [22]Kinugasa A, Tsunamoto K, Furukawa N, et al.Fatty liver and its fi-brous changes found in simple obesity of children[J].J Pediatr Gas-troenterol Nutr, 1984, 3 (3) :408-414. [23]Fan JG, Zhu J, Li XJ, et al.Fatty liver and the metabolic syn-drome among Shanghai adults[J].J Gastroenterol Hepatol, 2005, 20 (12) :1825-1832. [24]Park SH, Jeon WK, Kim SH, et al.Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J].J Gastro-enterol Hepatol, 2006, 21 (1Pt1) :138-143. [25]Park SH, Kim BI, Yun JW, et al.Insulin resistance and C-reac-tive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men[J].J Gastroenterol Hepatol, 2004, 19 (6) :694-698. [26]Farrell GC.Non-alcoholic steatohepatitis:what is it, and why is it important in the Asia-Pacific region-[J]J Gastroenterol Hepatol, 2003, 18 (2) :124-138. [27]Chen CH, Huang MH, Yang JC, et al.Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan:metabolic significance of nonalcoholic fatty liver disease in nonobese adults[J].J Clin Gastroenterol, 2006, 40 (8) :745-752. [28]Wong VW, Hui AY, Tsang SW, et al.Metabolic and adipokine pro-file of Chinese patients with nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol, 2006, 4 (9) :1154-1161. [29]Hasan I, Gani RA, Machmud R, et al.Prevalence and risk factors for nonalcoholic fatty liver in Indonesia[J].J Gastroenterol Hepatol, 2002, 17 (Suppl) :S154. [30]Leung NW.Epidemiological study:nonalcoholic fatty liver disease in Hong Kong Chinese[J].Hepatology, 2004, 40 (Suppl1) :582A. [31]Duseja A, Chawla Y.Nonalcoholic fatty liver disease in India--How much-Howsoon-[J].Trop Gastoenterol, 2005, 26 (1) :1-3. [32]Malik A, Cheah PL, Hilmi IN, et al.Non-alcoholic fatty liver dis-ease in Malaysia:A demographic, anthropometric, metabolic and histological study[J].J Dig Dis, 2007, 8 (1) :58-64. [33]Agarwal SR, Malhotra V, Sakhuja P, et al.Clinical biochemical and histological profile of nonalcoholic steatohepatitis[J].Indian J Gas-troenterol, 2001, 20 (5) :183-186. [34]Nomura H, Kashiwagi S, Hayashi J, et al.Prevalence of fatty liver in a general population of Okinawa, Japan[J].Jpn J Med, 1988, 27 (2) :142-149. [35]Oshibuchi M, Nishi F, Sato M, et al.Frequency of abnormalities detected by abdominal ultrasound among Japanese adults[J].J Gas-troenterol Hepatol, 1991, 6 (2) :165-168. [36]Ikai E, Ishizaki M, Suzuki Y, et al.Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hy-pertension in alcohol consumers and obese people[J].J HumHyper-tens, 1995, 9 (2) :101-105. [37]Omagari K, Kadokawa Y, Masuda J, et al.Fatty liver in non-al-coholic non-overweight Japanese adults:Incidence and clinical characteristics[J].J Gastroenterol Hepatol, 2002, 17 (10) :1098-105. [38]Lai SW, Tan CK, Ng KC, et al.Epidemiology of fatty liver in a hospital-based study in Taiwan[J].South Med J, 2002, 95 (11) :1288-1292. [39]Lin YD, Lo HM, Chen DJ.Sonographic fatty liver, overweight and ischemic heart disease[J].World J Gastroenterol, 2005, 11 (31) :4838-4842. [40]Hwang SJ, Luo JC, Chu CW, et al.Hepatic steatosis in chronic hepatitis C virus infection:prevalence and clinical correlation[J].J Gastroenterol Hepatol, 2001, 16 (2) :190-195. [41]Liu CJ, Jeng YM, Chen PJ, et al.Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver dis-ease in chronic hepatitis C[J].Antivir Ther, 2005, 10 (3) :405-415. [42]Liu CJ, Chen PJ, Jeng YM, et al.Serumadiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C[J].J Hepatol, 2005, 43 (2) :235-242. [43]Hsu CS, Liu CJ, Liu CH, et al.High hepatitis C viral load is asso-ciated with insulin resistance in patients with chronic hepatitis C[J].Liver Int, 2008, 28 (2) :271-277. [44]Hsu CS, Liu CJ, Liu CH, et al.Metabolic profiles in patients with chronic hepatitis C:a case-control study[J].Hepatol Int, 2008, 2 (2) :250-257. [45]Hsu CS, Liu CH, Liu CJ, et al.Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype1or2infection[J].Am J Gastroenterol, 2009, 104 (3) :598-604. [46]Dai CY, Huang JF, Hsieh MY, et al.Insulin resistance predicts re-sponse to peginterferon-alpha/ribavirin combination therapy in chro-nic hepatitis C patients[J].J Hepatol, 2009, 50 (4) :712-718. [47]Huang JF, Dai CY, Hwang SJ, et al.Hepatitis C viremia increases the association with type2diabetes mellitus in a hepatitis B and C endemic area:an epidemiological link with virological implication[J].Am J Gastroenterol, 2007, 102:1237-1243. [48]Miyanari Y, Atsuzawa K, Usuda N, et al.The lipid droplet is an important organelle for hepatitis C virus production[J].Nature Cell Biol, 2007, 9 (9) :1089-1097. [49]Dai CY, Chuang WL, Ho CK, et al.Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels:a com-munity-based study[J].J Hepatol, 2008, 49 (1) :9-16. [50]Wang CC, Hsu CS, Liu CJ, et al.Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis[J].J Gastroenterol Hepatol, 2008, 23 (5) :779-782. [51]Chen CL, Yang HI, Yang WS, et al.Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:A fol-low-up study in Taiwan[J].Gastroenterology, 2008, 135 (1) :111-121. [52]Yu MW, Shih WL, Lin CL, et al.Body-mass index and progres-sion of hepatitis B:Apopulation-based cohort study in men[J].J Clin Oncol, 2008, 26 (34) :5576-5582. [53]Wong GL, Wong VW, Choi PC, et al.Metabolic syndrome increa-ses the risk of liver cirrhosis in chronic hepatitis B[J].Gut, 2009, 58 (1) :111-117. -
下载:
